Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer

Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL

Harnessing dendritic cells to generate cancer vaccines

Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers

Brain tumor immunotherapy with type-1 polarizing strategies

Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer

Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells

Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus

Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo

Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens